Figure 4
From: Detection and Differentiation of Breast Cancer Sub-Types using a cPLA2α Activatable Fluorophore
DDAO arachidonate fluorescence in cPLA2α knockdown 4175-Luc+ cells. (A) Protein expression in 4175-Luc+ cells, cPLA2α CRISPR knockout plasmid transfected cells, and scrambled CRISPR knockout plasmid transfected cells. Full gel is presented. (B) Quantitated cPLA2α protein levels, taken from (A), relative to beta-tubulin. Significant knockdown of cPLA2α protein was observed in cPLA2α CRISPR plasmid transfected cells (p = 8.2 × 10−7). (C) Relative fluorescence of DDAO arachidonate or DDAO palmitate with time in cPLA2α knockdown cell lines. (D) Quantitated relative fluorescence at 120 minutes, taken from (C). Significant reduction of fluorescence was observed in cPLA2α knockdown cells treated with DDAO arachidonate (p = 1.58 × 10−6). No significant changes in fluorescence were observed when treated with DDAO palmitate.
